|
|
| Gram-negative Neisseria meningitidis (N.men) is an important contributor to bacterial meningitis. Of the estimated 1.2 million cases which occur each year (WHO Figures), N.men is thought to be responsible for around 40% of the total where 5 main serogroups ACWY and B are responsible for the majority of disease.
Conjugated vaccines to prevent meningococcal disease have had successful impact especially in the United Kingdom (serogroup C, implemented 1999). In 2005, a newer quadrivalent conjugated vaccine with protection against ACWY serogroups, Menactra (MCV4) was recommended for use in US adolescents. To expand the market further new ACWY vaccines such as MenHibrix, Nimenrix (GSK), Menveo (Novartis, now FDA approved) and also Menactra (Sanofi Pasteur) are aiming for use in infants/toddlers. This MarketVIEW product gives a comprehensive vaccine value ($USD/volume 000s) forecast for all products within all age group indications in the critical US market for the next 10-15 years. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing recommendation/competitive and pricing scenarios. Please note: this is delivered as a Zip file. |
Related Markets
Vaccines Reports
- Triple Analysis: Prostate Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Melanoma, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Lymphoma, Cancer Vaccines and Protein Kinase Inhibitors
- Triple Analysis: Lung Cancer, Cancer Vaccines and Protein Kinase Inhibitors
